These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 455885)

  • 21. Transfer of propranolol and sotalol across the human placenta. Their effect on maternal and fetal plasma renin activity.
    Erkkola R; Lammintausta R; Liukko P; Anttila M
    Acta Obstet Gynecol Scand; 1982; 61(1):31-4. PubMed ID: 7046334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of oral verapamil therapy on antipyrine clearance.
    Rumiantsev DO; Piotrovskii VK; Riabokon OS; Slastnikova ID; Kokurina EV; Metelitsa VI
    Br J Clin Pharmacol; 1986 Nov; 22(5):606-9. PubMed ID: 3790408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of acute and chronic propranolol administration on antipyrine and paracetamol clearance in patients with chronic liver disease.
    Hayes PC; Bouchier IA
    Am J Gastroenterol; 1989 Jul; 84(7):723-6. PubMed ID: 2741882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of inflammation on the metabolism of antipyrine, lidocaine and propranolol in isolated rat hepatocytes.
    Chindavijak B; Belpaire FM; Bogaert MG
    Pharmacology; 1988; 36(4):279-82. PubMed ID: 3380881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of sotalol and propranolol in mild to moderate essential hypertension.
    Pessina AC; Hlede M; Morandin F; Casiglia E; Gava R; Agnoletto V; Locatelli C; Dal Palu C
    Int J Clin Pharmacol Res; 1983; 3(1):41-5. PubMed ID: 6679506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Propranolol does not further decrease the clearance of antipyrine in patients with alcoholic cirrhosis.
    Larrey D; Lebrec D; Bercoff E; Pessayre D
    Clin Sci (Lond); 1983 Aug; 65(2):203-5. PubMed ID: 6602683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics, central nervous system uptake, and lipid solubility of propranolol, acebutolol, and sotalol.
    Arendt RM; Greenblatt DJ; deJong RH; Bonin JD; Abernethy DR
    Cardiology; 1984; 71(6):307-14. PubMed ID: 6151871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alteration of the pharmacokinetics and metabolism of propranolol and antipyrine elicited by indwelling catheters in the rat.
    Chindavijak B; Belpaire FM; De Smet F; Bogaert MG
    J Pharmacol Exp Ther; 1988 Sep; 246(3):1075-9. PubMed ID: 3418510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatic blood flow and drug metabolism in patients on enzyme-inducing anticonvulsants.
    Pirttiaho HI; Sotaniemi EA; Pelkonen RO; Pitkänen U
    Eur J Clin Pharmacol; 1982; 22(5):441-5. PubMed ID: 7117357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Studies of the absorption and removal of propranolol in hypertensive patients during therapy.
    Chidsey CA; Morselli P; Bianchetti G; Morganti A; Leonetti G; Zanchetti A
    Circulation; 1975 Aug; 52(2):313-8. PubMed ID: 1149212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Quantification of the drug-metabolizing enzyme system in liver diseases: a comparison between antipyrine saliva clearance and the aminopyrine breath test].
    von Mandach U; Jost G; Preisig R
    Schweiz Med Wochenschr; 1985 May; 115(19):651-8. PubMed ID: 3923620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sotalol kinetics in renal insufficiency.
    Blair AD; Burgess ED; Maxwell BM; Cutler RE
    Clin Pharmacol Ther; 1981 Apr; 29(4):457-63. PubMed ID: 7471612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Saliva and plasma clearance of antipyrine as reflectors of liver function.
    Luoma PV; Sotaniemi EA
    Eur J Drug Metab Pharmacokinet; 1981; 6(4):261-4. PubMed ID: 7333326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug metabolism in epileptics: in vivo and in vitro correlations.
    Sotaniemi EA; Pelkonen RO; Ahokas J; Pirttiaho HI; Ahlqvist J
    Br J Clin Pharmacol; 1978 Jan; 5(1):71-6. PubMed ID: 619937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of halothane on drug disposition: contribution of changes in intrinsic drug metabolizing capacity and hepatic blood flow.
    Reilly CS; Wood AJ; Koshakji RP; Wood M
    Anesthesiology; 1985 Jul; 63(1):70-6. PubMed ID: 4014773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug metabolism in liver disease: activity of hepatic microsomal metabolizing enzymes.
    Farrell GC; Cooksley WG; Powell LW
    Clin Pharmacol Ther; 1979 Oct; 26(4):483-92. PubMed ID: 487696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impairment of hepatic drug metabolism in alcoholics.
    Harman AW; Frewin DB; Priestly BG; Alexander CB
    Br J Clin Pharmacol; 1979 Jan; 7(1):45-8. PubMed ID: 760741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of zidovudine therapy in patients with HIV infection on endogenous interferon plasma levels and the hepatic cytochrome P450 enzyme system.
    Brockmeyer NH; Barthel B; Mertins L; Goos M
    Chemotherapy; 1998; 44(3):174-80. PubMed ID: 9612607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized double blind trial comparing sotalol and propranolol in chronic ventricular arrhythmia.
    Kubac G; Klinke WP; Grace M
    Can J Cardiol; 1988 Oct; 4(7):355-9. PubMed ID: 3067834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of pioglitazone on endotoxin-induced decreases in hepatic drug-metabolizing enzyme activity and expression of CYP3A2 and CYP2C11.
    Ueyama J; Kitaichi K; Nadai M; Iwase M; Tomyo N; Kanazawa H; Suzuki R; Takagi K; Takagi K; Hasegawa T
    Eur J Pharmacol; 2004 Sep; 498(1-3):257-65. PubMed ID: 15364003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.